James Hocker to Diagnosis, Differential
This is a "connection" page, showing publications James Hocker has written about Diagnosis, Differential.
Connection Strength
0.631
-
Serum Monitoring and Phenotype Identification of Stage I Non-Small Cell Lung Cancer Patients. Cancer Invest. 2017 Oct 21; 35(9):573-585.
Score: 0.132
-
Discriminating patients with early-stage pancreatic cancer or chronic pancreatitis using serum electrospray mass profiling. Cancer Lett. 2015 Apr 10; 359(2):314-24.
Score: 0.110
-
Distinguishing patients with stage I lung cancer versus control individuals using serum mass profiling. Cancer Invest. 2014 May; 32(4):136-43.
Score: 0.103
-
Distinguishing non-small cell lung adenocarcinoma patients from squamous cell carcinoma patients and control individuals using serum profiling. Cancer Invest. 2012 Feb; 30(2):180-8.
Score: 0.088
-
Serum discrimination of early-stage lung cancer patients using electrospray-ionization mass spectrometry. Lung Cancer. 2011 Nov; 74(2):206-11.
Score: 0.085
-
Distinguishing patients with idiopathic epilepsy from solitary cysticercus granuloma epilepsy and biochemical phenotype assessment using a serum biomolecule profiling platform. PLoS One. 2020; 15(8):e0237064.
Score: 0.040
-
Distinguishing and phenotype monitoring of traumatic brain injury and post-concussion syndrome including chronic migraine in serum of Iraq and Afghanistan war veterans. PLoS One. 2019; 14(4):e0215762.
Score: 0.037
-
Distinguishing neurocysticercosis epilepsy from epilepsy of unknown etiology using a minimal serum mass profiling platform. Exp Parasitol. 2018 Sep; 192:98-107.
Score: 0.035